혈액종양의 분자세포유전학 molecular cytogenetics in hematologic malignancy
DESCRIPTION
Chromosome. Nucleus. 혈액종양의 분자세포유전학 Molecular Cytogenetics in hematologic Malignancy. Cell. DNA. Historical Backgroud. Philadelphia chromosome (Ph) 1970 Banding technique 1970 t(9;22) in CML 1973 t(8;21) in AML-M2 t(8;14) in Burkitt lymphoma/Leukemia - PowerPoint PPT PresentationTRANSCRIPT
Back to Basic혈액종양의 분자세포유전학Molecular Cytogenetics in hematologic Malignancy
Nucleus
Cell
Chromosome
DNA
Back to Basic
1960 Philadelphia chromosome (Ph)
1970 Banding technique1970 t(9;22) in CML
1973 t(8;21) in AML-M2 t(8;14) in Burkitt lymphoma/Leukemia
1977 t(15;17) in AML-M3, t(4;11) 1979 High-resolution banding technique
19801982 t(9;11) in AML-M5a, inv(3) in AML1983 inv(16) in AML-M4E 1984 t(1;19) in ALL
t(1;3) in AML with dysmegakaryopoiesis
1990 Molecular cytogenetics (FISH, CGH)
Historical Backgroud
Back to Basic
1980 1983 MYC-IGH t(8;14) 1984 BCR-ABL1 t(9;22) IGH-BCL2 t(14;18) 1990 1991 MLL-AFF1 t(4;11) E2A-PBX1 t(1;19)
PML-RARA t(15;17) RUNX1-RUNX1T1 t(8;21)
DEK-NUP214 t(6;9)1993 CBFB-MYH11 inv(16) MLL-MLLT3 t(9;11)1997 TEL-AML1 t(12;22)
Cytogenetic & Gene Rearrangement
Back to Basic
KimSW, et al.: Banding patterns of normal human chromosomes. The Seoul Journal of Medicine 21(2):133-137(1980).
조혈기질환에 있어서 골수세포 염색체 분석에 관한 연구 . 대한혈액학회지 23(2),1988
Karyotype No.
t(22q;9q) 7
22q- 622q-. -9 149,XXX,+9,+21 1Normal 6
21
Table 4. Karyotypic pattern in cases with CML
Cytogenetic Studies for Hematologic Malignancies in Korea
Back to Basic
Philadelphia Chromosome (=Ph) der(22)t(9;22)(q34.1;q11.21)
q34ABL
q11.2BCR
Ph (formerly Ph1) may be used in text, but not in the description of the karyotype, where der(22)t(9;22)(q34;q11.2) is recommended.
Back to Basic
50,XX,+8,t(9;22)(q34;q11.2),+10,+19,+der(22)t(9;22)(q34.1;q11.21)
CML Blast Crisis - Karyotype
Back to BasicPractical Use of Cytogenetics in CML
Advantages of Cytogentics, compared to molecular DNA studies for BCR gene rearrangement
Distinguish betwn variant Ph and standard t(9;22)Dectect other abnormalities : +8, i(17q),+Ph,+19Predict or confirm blast crisisGive information regarding percentage of normal vs
abnormal cellsValuable after BMT to follow engraftment of the donor
cells and identify possible relapse
Back to BasicAML-M2 with t(8;21)(q22;q22)
Usually AML-M2, occasionally M1 & M4Young individuals with good remission rateBlasts containing a single thin Auer rodRT-PCR : RUNX1-RUNX1T1 fusion transcript
Back to BasicAPL with t(15;17)(q22;q21), PML/RARA
G-banding : t(15;17)(q22;q21) & Variants of t(15;Var;17), t(11;17), t(5;17)RT-PCR, FISH : PML/RARA fusion transcript
PML RARAPML/RARA
From highly fatal to highly curable
ATRA (all-trans retinoic acid) & ATO (arsenic trioxide)
Back to BasicAML-M4Eo with inv(16)
Young patients, organomegaly, abnormal eosinophilsSpecifically associated with M4Eo in over 50% of casesFavorable prognosis, High incidence of CNS relapse
MYH11
CBFB CBFB-MYH11
Back to BasicAcute Myeloid Leukemia and Related Neoplasms
AML with recurrent genetic abnormalities t(8;21), RUNX1-RUNX1T1 t(15;17), PML/RAR inv(16), CBF/MYH11 t(9;11), MLLT3/MLL t(6;9), DEK/NUP214 inv(3) or t(3;3), RPN1-EVI1 t(1;22), RBM15-MKL1
Acute myeloid leukemia with myelodysplasia-related changes Therapy-related myeloid neoplasms Acute myeloid leukemia, not otherwise specified Myeloid sarcoma Myeloid proliferations related to Down syndrome Blastic plasmacytoid dendritic cell neoplasm
Proposed WHO Classification
Back to Basic
Normal ChromosomeNormal Chromosomedel 5qdel 5q-7, del 7q-7, del 7qdel 9qdel 9qdel 20qdel 20q+8+8complex defectscomplex defectst(1;3), t(2;11)t(1;3), t(2;11)
t(3;3), inv(3)t(3;3), inv(3)t(6;9), inv(16)t(6;9), inv(16)t(8;21)t(8;21)t(9;22)t(9;22)t(v;11)t(v;11)t(15;17)t(15;17)
MDSMDS
AMLAML
Back to BasicMyeloid Malignancy
Secondary to Radiotherapy or Chemotherapy
Clinical featuresAML-M1,M2,M6Lower remission rate and long-term reponse
CytogeneticsUsually absence of t(8;21), t(15;17) & inv(16)
Usually complex karyotype Common abnormalities:
-5, del(5q) in chemotherapy, -7, del(7q) in radiation therapy,
Abnormalities of 3p, 11q23, 12p, and 17
Back to Basic
Cytogenetics in Acute Lymphoblastic Leukemia
Poorly spread, shortFuzzy chromosomesIndistinct bands
Low success rate 50% in conventional culture76% Clarkson (1985)
Back to Basic
Ploidy Groups in Childhood Ploidy Groups in Childhood ALLALL Hyperdiploid >50 28%
Early pre-B immunophenotypeFound at the age of 2-10 yearsLower WBC count, Favorable prognosis
Hyperdiploid 47-49 13% Diploid 46 9% Pseudodiploid 46 38% Hypodiploid <46 6%
Back to BasicPrecursor Lymphoid Neoplasm
B lymphoblastic leukemia/lymphoma, NOS B lymphoblastic leukemia/lymphoma with recurrent genetic
abnormalities – t(9;22)(q34;q11.2); BCR-ABL1 – t(v;11q23); MLL rearranged – t(12;21)(p13;q22) TEL-AML1 (ETV6-RUNX1) – hyperdiploidy – hypodiploidy – t(5;14)(q31;q32) IL3-IGH – t(1;19)(q23;p13.3);TCF3-PBX1
T lymphoblastic leukemia/lymphoma
Proposed WHO Classification
Back to Basic
Clinicalfeature
No single ‘gold standard’
“Real” disease entity
Genetic featuresMolecular &cytogenetics
Morphology
WHO Classification
Immunophenotype
Back to Basic
Back to BasicAML with specific chromosome defects
Chromosome defect
Breakpoint FAB FrequencyKorea1) USA2)
del 5q 5q31 & q35 M2,M1 4 1
-7/del 7q 7q31.2 & q36 M2,M1,M4~7 5 3
t(6;9) 6p22.2 & 9q34.1 M2,M1,M4 1 2
t(8;21) 8q22.1 & 21q22.3 M2,M4,M1 22 20
+8 M2,M1,M4~6 20 18
t(9;22) 9q34.1 & 22q11.21 M1,M2 3 8
t(V;11) 11q23.3 M4,M5a,M2 2 9
t(15;17) 15q22 & 17q21 M3 19 6
inv 16 16p13.2 & q22.1 M4 2 9
Complex M2,M1,M4 23 14
Others M0 ~ M7 15 17
1) Hallym University Medical Center (1995)2) University of Minnesota Medical School
Back to BasicCytogenetics Technologies
Karyotyping– Provides a visual examination of the entire genome– the best coverage but not the best resolution (≥ 5 Mb)– Banding resolution differs from preparation to preparation
FISH– Sensitive (high resolution)– Only provides information on tested regions, other aberrations will
NOT be tested, i.e. not genome view– M-FISH(Multi-FISH, Spectral karyotyping)
Array-based Copy Number / CGH AnalysisSingle step global genome scan prevents FISHing expedition – BAC (Bacterial Artificial Chromosome) Array
• Requires well characterized and high resolution clones– High Resolution Oligonucleotide Microarray
• Highest resolution.• Precise identification of gains and losses of genetic material.
Back to BasicClinical Application of FISHClinical Application of FISH
Microdeletion syndromes• Prader-Willi/Angelman syndrome• DiGeorge/CATCH 22 syndrome • Williams syndrome etc.
Marker chromosome
Hematologic malignancies• t(9;22): abl/bcr• t(15;17): PML/RARa • 11q23: MLL• t(12;21): TEL/AML1
BMT follow-up using X/Y
46,XY,t(9;22)(q34;q11.2)
Back to Basic
1. Preparation of tumor sample 1. Preparation of tumor sample 2. Tumor cell culture2. Tumor cell culture
Culture MediaCulture MediaFBS (11-20%)FBS (11-20%)AntibioticsAntibiotics AdditivesAdditivesTumor cellsTumor cells
2. Harvest 2. Harvest 1) Colcemid (0.01-0.1mcg/mL) treatment 1) Colcemid (0.01-0.1mcg/mL) treatment 2) Hypotonic (0.050-0.075M KCl) treatment2) Hypotonic (0.050-0.075M KCl) treatment 3) Fixation3) Fixation 4) Slide preparation4) Slide preparation3. Staining and analysis 3. Staining and analysis
Solid Tumor CytogeneticsSolid Tumor Cytogenetics
InsulinInsulinTransferrinTransferrinHydrocortisoneHydrocortisoneEDGFEDGF
Back to BasicSolid Tumor Abnormalities
der(1) breast carcinomasdel(1p) colorectal adenomadel(3)(p12p14) breast carcinomasdel(3)(p14p23) small cell carcinoma of lungs
del(3p)renal cell carcinoma, non-small cell lung cancer
del(7)(q21q31) uterine leiomyomas del(9)(p13) malignant melanomadel (11)(p13) Wilm's tumordel(22q) or -22 meningiomas i(6)(p10) retinoblastomai(8)(q10) uveal melanomai(12)(p10) testicular germ cell tumorsi(17)(q10) primitive neuroectodermal tumorinv(10)(q11q21) papillary carcimoma of the thyroidt(1;17)(p36;q12) neuroblastoma
Back to Basic
inv(10)(q11q21) papillary carcimoma of the thyroidt(1;17)(p36;q12) neuroblastomat(2;13)(q35;q14) alveolar rhabdomyosarcomat(3;8)(p21;q12) pleomorphic ademoma of salivary glandst(3;12)(q27-28;q13-15) sporadic typical lipomast(9;22)(q22;q11-12) extraskeletal myxoidchondrosarcoma
t(11;19)(q21;p11)mucoepidermoid carcinoma, adenolymphoma of salivary gland
t(11;22)(p13;q12)intraabdominal desmoplastic small round cell tumor
t(11;22)(q24;q12)Askins tumor, Ewings sarcoma, esthesioneuroblastoma
t(12;14)(q14-15;q23-24) uterine leiomyomast(12;16)(q13;p11.2) myxoid liposarcomat(X;1)(p11;q21) malignant papillary renal cell carcinomat(X;18)(p11.2;q11.2) synovial sarcoma
Back to Basic
Back to Basic
Back to Basic
1983 19851988 1991 19940
5000
10000
15000
20000
25000
1983 19851988 1991 1994
Solid TumorsMalig LymphomaHemat Malignancy
“Catalog of Chromosome Aberrations in Cancer ”
Back to BasicCancer Cytogenetics (2009)
CONTENTS
1) A New Approach to an Old Problem 2) Cytogenetic Methods 3) Cytogenetic Nomenclature 4) Nonrandom Chromosome Abnormalities in Cancer - An Overview
5-10) Hematologic Malignancies : AML, MDS, CML, CMPN, ALL, Mature B- and T-Cell Neoplasms and Hodgkin Lymphoma
11-23) Solid Tumors : Upper Aerodigestive tract, Lung, Digestive Tract, Urinary Tract, Breast, Genital Organs, Endocrine Glands, Nervous System, Eye, Skin, Bone, Soft Tissue Tumors